Current Edition

acute heart failure

Eli Lilly and Boehringer Ingelheim’s Jardiance stays on its heart failure winning streak⁠—this time in acute patients

Three months after earning an approval to treat chronic heart failure with their SGLT2 inhibitor Jardiance, Eli Lilly and Boehringer Ingelheim have posted new data …

Continue Reading →
Boehringer Ingelheim

Lilly and Boehringer’s Jardiance shows benefits for those with ‘intimately linked’ heart failure and kidney disease

Heart failure and chronic kidney disease often go hand in hand. And when they do, the risk of death and hospitalization increase. A new analysis …

Continue Reading →